A novel tropomyosin-related kinase A inhibitor, KK5101 to treat pancreatic cancer

Tropomyosin-related kinase A (TrkA) plays important roles in tumor cell growth and survival signaling and contributes to chemo-resistance in pancreatic cancer. Therefore, we developed KK5101, a novel TrkA target inhibitor and assessed its anti-cancer effects and investigated underlying mechanism of action in pancreatic cancer. KK5101 was characterized to inhibit TrkA selectively and potently by protein binding assay. It effectively inhibited the growth and proliferation of pancreatic cancer cells.

Source: Cancer Letters - March 29, 2018 Category: Cancer & Oncology Authors: Zhenghuan Fang, Boreum Han, Kyung Hee Jung, Ju-Hyeon Lee, Ashraf Kareem El-Damasy, Changdev G. Gadhe, Soo Jung Kim, Hong Hua Yan, Jung Hee Park, Ji Eun Lee, Yeo Wool Kang, Ae Nim Pae, Gyochang Keum, Soon-Sun Hong Tags: Original Articles Source Type: research